Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TBX101
- Development stage
- Preclinical
- Lead developer
- Trobix Bio
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Nanoparticles → Drug Delivery Systems, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
TBX101 is a preclinical, phage-based nanomedicine in development by the Israeli company Trobix Bio. It is engineered to combat antimicrobial resistance by targeting antibiotic-resistant bacteria residing in the gut. The therapy utilizes a platform that combines engineered phages with CRISPR technology to deliver DNA payloads specifically to these 'superbugs'. The intended mechanism is to modify the bacteria to restore their sensitivity to antibiotics, addressing a critical unmet need in hospitalized patients at high risk. [2, 5, 6] The technology platform behind TBX101 includes the proprietary ActiSense™ and GoTrap™ technologies.
02
Targets
Shigella spp. (Shigella species)
Beyond the preview
Go deeper on TBX101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TBX101.